产品说明书
Pentagastrin
 |
同义名 : | "ICI-50123;AY 6608;Petogasrin;Peptavlon;Pentagastrinum; |
| CAS号 : | 5534-95-2 | |
| 货号 : | A459112 | |
| 分子式 : | C37H49N7O9S | |
| 纯度 : | 99%+ | |
| 分子量 : | 767.891 | |
| MDL号 : | MFCD00076515 | |
| 存储条件： |
粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 35 mg/mL(45.58 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Pentagastrin (ICI-50123) is identified as a potent, selective antagonist of the Cholecystokinin B (CCKB) receptor, with IC50 values of 11 nM for CCKB and 1100 nM for CCKA receptors. It plays a significant role in enhancing gastric mucosal defense mechanisms against acid and provides protection to the gastric mucosa from experimental damage[1].[2]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01699113 | Hypergastrinaemia | Phase 1 | Completed | - | United Kingdom ... 展开 >> Hammersmith Medicines Research London, United Kingdom 收起 << |
| NCT00625495 | Gastroesophageal Reflux Diseas... 展开 >>e 收起 << | Phase 4 | Completed | - | - |
| NCT00001229 | - | Completed | - | United States, Maryland ... 展开 >> National Heart, Lung and Blood Institute (NHLBI) Bethesda, Maryland, United States, 20892 收起 << | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.30mL 0.26mL 0.13mL |
6.51mL 1.30mL 0.65mL |
13.02mL 2.60mL 1.30mL |
| 参考文献 |
|---|